Authors
Latest:
The Role of Age in Bone Marrow and Stem Cell Transplants for MDSRonald L. Paquette, MD, discusses how age impacts the use of bone marrow and stem cell transplants in patients with myelodysplastic syndrome.
Latest:
The Future of Upper Gastric Cancer TreatmentDavid Zhen, MD, provides advice to oncologists treating patients with upper gastric cancer and offers closing thoughts on the future treatment landscape, highlighting challenges and unmet needs.
Latest:
Future Outlooks in an Evolving Landscape for R/R DLBCLDr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.
Latest:
Recent Advances in mCSPC and Advice for Community OncologistsSheela Tejwani, MD, highlights some exciting recent trial data and shares clinical pearls for community oncologists treating mCSPC.
Latest:
Addressing MDS Treatment Gap Post Hypomethylating FailureThe frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.
Latest:
CAR T-Cell Therapy Access Remains Elusive, But Solutions May Be Closer Than ExpectedWidespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.
Latest:
Tolerability of Teclistamab Improved with Step-Up DosingIn a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.
Latest:
Defining the Role of Stem Cell Transplant in T-Cell LymphomaJohn Lister, MD, discusses the current role of stem cell transplant in the treatment of T-cell lymphoma, and some of the latest advances in the space.
Latest:
Clinical Pearls for Community Oncologists Treating Patients With RRMMRafael Fonseca, MD, envisions a future where bispecific antibodies and CAR T-cell therapy, currently used in advanced stages of multiple myeloma treatment, can offer potential cure for patients, and emphasizes the importance of advocating for their broader application in community settings.
Latest:
Novel Anti-CD19 CAR T-Cell Therapy Shows Efficacy in Multiple BCL SubtypesManali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.
Latest:
Recent Advancements in Stem Cell TransplantsAmer Assal, MD, discusses recent advancements in the field of bone marrow and stem cell transplants at the American Society of Hematology 2023 Annual Meeting.
Latest:
Considering Mutations and Resistance in Lung Cancer to Improve Precision MedicineAnne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses hard-to-treat lung cancer and how due to recent lung cancer innovations and treatment options, the tumor is becoming increasingly heterogeneous.
Latest:
Real-World Implications of the IMpower133 Trial in ES-SCLCEric S. Nadler, MD of Texas Oncology, discusses the real-world patient characteristics and treatment duration of the immunotherapy combination treatment of the IMpower133 trial in patients with extensive-stage small cell lung cancer.
Latest:
Revumenib Shows Potential in Phase 2 Trial of Children and Adults With R/R KMT2Ar Acute LeukemiaA new targeted therapy showed promising response rates in pediatric and adult patients with relapsed/refractory KMT2A rearranged acute leukemia.
Latest:
Exploring Current and Future Treatment in Patients With DLBCLMitul Gandhi, MD, discusses the current landscape for patients with diffuse large B-cell lymphoma and what may be coming in the future.
Latest:
Unmet Needs in the Treatment of Patients With MDSAmy Dezern, MD, MHS, closes her discussion by emphasizing the need for more treatments in MDS.
Latest:
Managing Symptoms of Diarrhea Improves Medication Adherence in Patients Treated With AbemaciclibDose escalation may be beneficial for patients starting treatment regimens with a high incidence of toxicities that may lead to abrupt patient self-discontinuation.
Latest:
Risk Information Can Influence Clinical Decision-Making in MelanomaCutaneous melanoma is disproportionately lethal among skin cancers, and as incidence rates of cutaneous melanoma continue to rise in the United States, so does the importance of managing melanoma cases in alignment with personalized prognoses.
Latest:
Clinical Implications and Positioning of Imetelstat in Lower-Risk MDSClosing remarks on the overall clinical implications of imetelstat data, and patient populations that could benefit the most from it.
Latest:
Discussing Treatment Options for Patients With HCCJoan Culpepper-Morgan, MD, provides an overview on different treatment approaches for patients with hepatocellular carcinoma.
Latest:
Multiple Myeloma Treatment Paradigm Improved Markedly In Recent YearsKenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.
Latest:
Unmet Needs of AML and Advice for Community OncologistsCourtney DiNardo, MD, concludes with discussing some challenges faced when treating patients with AML and shares some advice for community oncologists treating acute myeloid leukemia.
Latest:
An Update on Current and Emergent Therapies for Essential ThrombocytosisThe therapeutic landscape for myeloproliferative neoplasms is shifting toward a goal of meaningful disease modification.
Latest:
Next Steps for Trastuzumab Emtansine After the KAMILLA TrialRachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Latest:
Graff on Using the Signatera Assay to Assess ctDNA in Early Breast CancerStephanie L. Graff, MD, discusses what a community oncologist should know about her presentation on the Signatera assay in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer after adjuvant abemaciclib and endocrine therapy.
Latest:
Bladder Cancer: New Trials Target Local Delivery, Bladder PreservationStephen Williams, MD, MBA, MS, FACS, FACHE, discusses new and exciting developments in the bladder cancer treatment landscape.
Latest:
Using ctDNA in Stage II Colon CancerCristian Tomasetti, discusses the role of circulating tumor-DNA after surgery in patients with stage II colon cancer.
Latest:
Enhancing Patient-Centered Prostate Cancer Care CoordinationA discussion on streamlining patient care processes between urologists and medical oncologists while maintaining treatment continuity and minimizing disruptions for patients with prostate cancer.
Latest:
EP. 9A: The Rationale for CDK4/6 Inhibition in ES-SCLC and Updates on Trilaciclib Clinical Trial DataIn the fifth interview of the series, medical oncologist and hematologist Dr. Jerome H. Goldschmidt from Blue Ridge Cancer Care elaborates on the rationale for use of CDK4/6 inhibitors such as trilaciclib for prevention of chemotherapy-induced myelosuppression (CIM) in extensive-stage small cell lung cancer (ES-SCLC), and touches on recently presented data on trilaciclib.
